Lindsey Shapiro PhD,  science writer—

Ensifentrine, an investigational medication under review in the U.S. for chronic obstructive pulmonary disease (COPD), is effective across key patient subgroups, including when patients are separated by their history of lung exacerbations and type of background therapy. That’s according to recent pooled analyses from the ENHANCE-1 (NCT04535986) and…

Increases in new onset or recurring depression were seen among older Canadian adults with chronic obstructive pulmonary disease (COPD) during the early stages of the COVID-19 pandemic, a study shows. One in six patients without a history of depression before the pandemic developed it early on in it. For…

Tiotropium bromide dry inhalation powder for use with the LupinHaler device, a generic version of Spiriva HandiHaler, is now available in the U.S. as a maintenance treatment of chronic obstructive pulmonary disease (COPD), Lupin Pharmaceuticals announced. Generics are considered bioequivalent to their brand-name alternatives,…

Breyna, a generic version of Symbicort (budesonide-formoterol), has been launched in the U.S. for eligible people with chronic obstructive pulmonary disease (COPD) and asthma. The inhaled medication — the first Symbicort generic to be approved by the U.S. Food and Drug Administration — will become immediately available…

Lower vitamin D levels in the blood are associated with an increased risk of chronic obstructive pulmonary disease (COPD), especially among smokers, according to a study looking at U.K. data. Adults with COPD who had lower vitamin D levels before their diagnosis were also at an increased mortality…

People with diabetes or prediabetes are at an increased risk of developing chronic obstructive pulmonary disease (COPD), according to a recent study conducted in the U.K. A longer period of living with diabetes or a history of smoking further increases those odds. Among people who develop COPD, those who…

Pneumagen has secured £8 million (nearly $10 million) in investments to support the clinical development of its nasal spray, called Neumifil, for the prevention and treatment of virus-induced exacerbations in people with chronic obstructive pulmonary disease (COPD). “We are very pleased to announce this funding from our existing…

Dupixent (dupilumab) — a medication initially approved for exzema — was found to significantly reduce the number of disease exacerbations and to improve lung function in people with chronic obstructive pulmonary disease (COPD), meeting the primary and key secondary goals of the pivotal Phase 3 BOREAS trial. A similarly…

Therapeutic Solutions International (TSOI) reported discovering a new mechanism of action for JadiCell, its investigative stem cell therapy for chronic obstructive pulmonary disease (COPD) and other conditions. Working in animal models, scientists found that JadiCell’s protective effects were dependent on certain immune B-cells and a signaling molecule…

Chronic obstructive pulmonary disease (COPD) was associated with an increased risk of overall mortality, as well as higher chances of cardiovascular, respiratory, and cancer-associated deaths, in a group of people living in Finland, a recent study has found. While asthma was also linked to a higher mortality risk over…